Agilon Health Inc. (AGL) Misses Q3 EPS by 19c ; Offers Guidance

Agilon Health Inc. (NYSE: AGL) reported Q3 EPS of ($0.29), $0.19 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.45 billion versus the consensus estimate of $1.47 billion.

GUIDANCE:

Agilon Health Inc. sees FY2024 revenue of $6.05-6.06 billion, versus the consensus of $6.02 billion.

Agilon Health Inc. sees Q4 2024 revenue of $1.51-1.52 billion, versus the consensus of $1.46 billion.

For earnings history and earnings-related data on Agilon Health Inc. (AGL) click here.

You May Also Be Interested In

• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Agora Inc. (API) PT Raised to $6.80 at BofA Securities
• Eos Energy Enterprises (EOSE) PT Lowered to $5 at B.Riley